ClinicaliQ Trial Snapshot
- Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH) — Active Not Recruiting • Phase III • Diabetes / Metabolic • NCT04822181.
- Weekly semaglutide injections tested against placebo over 5 years to see if it helps fatty liver disease.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Semaglutide is a medicine studied in patients with NASH. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabetes in many countries. Participants will either get semaglutide or a dummy medicine - which treatment participants get is decided by chance. Participants will need to inject themselves with medicine under the skin. Participants will need to do this once a week. The study will last for about 5 years. Participants will have up to 21 clinic visits and 9 phone calls with the clinical staff…